These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 15006686

  • 1. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
    Hadj Tahar A, Grégoire L, Darré A, Bélanger N, Meltzer L, Bédard PJ.
    Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
    [Abstract] [Full Text] [Related]

  • 2. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [Abstract] [Full Text] [Related]

  • 3. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 4. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Mov Disord; 2006 Jan 01; 21(1):9-17. PubMed ID: 16127720
    [Abstract] [Full Text] [Related]

  • 5. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM.
    Exp Neurol; 2004 Aug 01; 188(2):471-9. PubMed ID: 15246846
    [Abstract] [Full Text] [Related]

  • 6. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN.
    J Pharmacol Exp Ther; 1999 Sep 01; 290(3):1034-40. PubMed ID: 10454475
    [Abstract] [Full Text] [Related]

  • 7. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ.
    Neuropharmacology; 2005 Aug 01; 49(2):165-73. PubMed ID: 15996565
    [Abstract] [Full Text] [Related]

  • 8. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM.
    J Pharmacol Exp Ther; 2010 Jun 01; 333(3):865-73. PubMed ID: 20231306
    [Abstract] [Full Text] [Related]

  • 9. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA.
    J Neurochem; 2007 Apr 01; 101(2):483-97. PubMed ID: 17359492
    [Abstract] [Full Text] [Related]

  • 10. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):446-54. PubMed ID: 20026151
    [Abstract] [Full Text] [Related]

  • 11. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM, Chase TN.
    Ann Neurol; 1996 May 16; 39(5):574-8. PubMed ID: 8619541
    [Abstract] [Full Text] [Related]

  • 12. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N, Morissette M, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.
    Neuropharmacology; 2013 Oct 16; 73():216-31. PubMed ID: 23756168
    [Abstract] [Full Text] [Related]

  • 13. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Grégoire L, Meltzer LT, Di Paolo T.
    J Mol Neurosci; 2009 Jun 16; 38(2):128-42. PubMed ID: 18704766
    [Abstract] [Full Text] [Related]

  • 14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 16; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 15. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar 16; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 16. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.
    Parkinsonism Relat Disord; 2009 Jul 16; 15(6):445-52. PubMed ID: 19196540
    [Abstract] [Full Text] [Related]

  • 17. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N, Grégoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T.
    Neuropharmacology; 2013 Mar 16; 66():355-64. PubMed ID: 22884464
    [Abstract] [Full Text] [Related]

  • 18. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
    Grégoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T.
    Parkinsonism Relat Disord; 2011 May 16; 17(4):270-6. PubMed ID: 21315648
    [Abstract] [Full Text] [Related]

  • 19. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M.
    Neuroscience; 2005 May 16; 132(2):409-20. PubMed ID: 15802193
    [Abstract] [Full Text] [Related]

  • 20. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E.
    Neurobiol Dis; 2007 May 16; 26(2):452-63. PubMed ID: 17350277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.